Plasma exchange in myasthenia gravis: effect on anti-AChR antibodies and other autoantibodies. 1986

S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder

Plasma exchange (PE) was performed in 6 patients with myasthenia gravis (MG). Acetylcholine receptor (AChR) antibodies and other MG-correlated antibodies were quantified each day before, during and after PE. The antibody concentrations decreased during PE with a consisting increase between two exchanges. Repeated PE induced a transient decline in the AChR antibody concentration. The clinical improvement was maximal during the week after PE and correlated in time with increasing concentrations of AChR antibodies.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody

Related Publications

S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
March 2012, Journal of neurology,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
November 1991, Neurology,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
June 1995, Journal of immunology (Baltimore, Md. : 1950),
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
January 1984, Neurology,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
July 2020, Neuromuscular disorders : NMD,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
July 2008, Journal of neuroimmunology,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
May 2011, Journal of neurology,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
November 1985, Acta neurologica Scandinavica,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
January 1987, Annals of the New York Academy of Sciences,
S Thorlacius, and A K Lefvert, and J A Aarli, and N E Gilhus, and K Halvorsen, and H Hofstad, and R Matre, and O Tönder
April 1989, Clinical and investigative medicine. Medecine clinique et experimentale,
Copied contents to your clipboard!